PATH-10. A CASE OF ADULT THALAMIC DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED WITH AN IMPRESSIVE RESPONSE TO RADIOTHERAPY AND CONCOMITANT PLUS ADJUVANT TEMOZOLOMIDE

MLA

Julien Rousseau, et al. “Path-10. A Case of Adult Thalamic Diffuse Midline Glioma, H3 K27-Altered with an Impressive Response to Radiotherapy and Concomitant Plus Adjuvant Temozolomide.” Neuro-Oncology, vol. 24, Nov. 2022, pp. vii151-vii152. EBSCOhost, https://doi.org/10.1093/neuonc/noac209.583.

APA

Julien Rousseau, Moujahed Labidi, Jean-Paul Bahary, Karl Bélanger, France Berthelet, & Sarah Lapointe. (2022). Path-10. A Case of Adult Thalamic Diffuse Midline Glioma, H3 K27-Altered with an Impressive Response to Radiotherapy and Concomitant Plus Adjuvant Temozolomide. Neuro-Oncology, 24, vii151-vii152. https://doi.org/10.1093/neuonc/noac209.583

Chicago

Julien Rousseau, Moujahed Labidi, Jean-Paul Bahary, Karl Bélanger, France Berthelet, and Sarah Lapointe. 2022. “Path-10. A Case of Adult Thalamic Diffuse Midline Glioma, H3 K27-Altered with an Impressive Response to Radiotherapy and Concomitant Plus Adjuvant Temozolomide.” Neuro-Oncology 24 (November): vii151-vii152. doi:10.1093/neuonc/noac209.583.